BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Griensven J, Phirum L, Choun K, Thai S, De Weggheleire A, Lynen L. Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia. PLoS One 2014;9:e88552. [PMID: 24533106 DOI: 10.1371/journal.pone.0088552] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 21.5] [Reference Citation Analysis]
2 De La Mata NL, Ly PS, Ng OT, Nguyen KV, Merati TP, Pham TT, Lee MP, Choi JY, Sohn AH, Law MG, Kumarasamy N. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer. Int J STD AIDS 2017;28:1282-91. [PMID: 28632481 DOI: 10.1177/0956462417699538] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Floridia M, Masuelli G, Tamburrini E, Spinillo A, Simonazzi G, Guaraldi G, Degli Antoni AM, Martinelli P, Portelli V, Dalzero S, Ravizza M. HBV coinfection is associated with reduced CD4 response to antiretroviral treatment in pregnancy. HIV Clin Trials 2017;18:54-9. [PMID: 28067163 DOI: 10.1080/15284336.2016.1276312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31:2035-2052. [PMID: 28692539 DOI: 10.1097/qad.0000000000001574] [Cited by in Crossref: 96] [Cited by in F6Publishing: 49] [Article Influence: 24.0] [Reference Citation Analysis]
5 Jiang T, Su B, Song T, Zhu Z, Xia W, Dai L, Wang W, Zhang T, Wu H. Immunological Efficacy of Tenofovir Disproxil Fumarate-Containing Regimens in Patients With HIV-HBV Coinfection: A Systematic Review and Meta-Analysis. Front Pharmacol 2019;10:1023. [PMID: 31572195 DOI: 10.3389/fphar.2019.01023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Chen M, Wong WW, Law MG, Kiertiburanakul S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim BL, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Chen YM. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. PLoS One 2016;11:e0150512. [PMID: 26933963 DOI: 10.1371/journal.pone.0150512] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
7 Bijker R, Kiertiburanakul S, Kumarasamy N, Pujari S, Sun LP, Ng OT, Lee MP, Choi JY, Nguyen KV, Chan YJ, Merati TP, Cuong DD, Ross J, Jiamsakul A; IeDEA Asia-Pacific. Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART. Antivir Ther 2020;25:131-42. [PMID: 32369040 DOI: 10.3851/IMP3358] [Reference Citation Analysis]
8 Pe R, Chim B, Thai S, Lynen L, van Griensven J. Advanced HIV Disease at Enrolment in HIV Care: Trends and Associated Factors over a Ten Year Period in Cambodia. PLoS One 2015;10:e0143320. [PMID: 26606057 DOI: 10.1371/journal.pone.0143320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
9 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Reference Citation Analysis]
10 Nikolopoulos GK, Paraskevis D, Psichogiou M, Hatzakis A. HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals. J Med Virol 2016;88:466-73. [PMID: 26288334 DOI: 10.1002/jmv.24357] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
11 Jiang TY, Hou JH, Su B, Zhang T, Yang Y, Liu ZY, Wang W, Guo CP, Dai LL, Sun LJ, Wu H. Demographic and clinical factors associated with immune reconstitution in HIV/HBV co-infected and HIV mono-infected patients: a retrospective cohort study. HIV Med 2020;21:722-8. [PMID: 33369028 DOI: 10.1111/hiv.13023] [Reference Citation Analysis]
12 Yang X, Su B, Zhang X, Liu Y, Wu H, Zhang T. Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders. J Leukoc Biol 2020;107:597-612. [PMID: 31965635 DOI: 10.1002/JLB.4MR1019-189R] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 14.5] [Reference Citation Analysis]
13 European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study. Clin Infect Dis 2020;70:404-15. [PMID: 30919882 DOI: 10.1093/cid/ciz253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rivera AS, Machenry S, Okpokwu J, Olatunde B, Ugoagwu P, Auwal M, Sule H, Agaba P, Agbaji OO, Thio CL, Murphy RL, Hawkins C. HBV co-infection is associated with persistently elevated liver stiffness measurement in HIV-positive adults: A 6-year single-centre cohort study in Nigeria. Antiviral Therapy 2021;26:106-16. [DOI: 10.1177/13596535211058262] [Reference Citation Analysis]
15 Huang YS, Chang SY, Sheng WH, Sun HY, Lee KY, Chuang YC, Su YC, Liu WC, Hung CC, Chang SC. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. PLoS One 2016;11:e0169228. [PMID: 28033344 DOI: 10.1371/journal.pone.0169228] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
16 Boateng R, Mutocheluh M, Dompreh A, Obiri-Yeboah D, Odame Anto E, Owusu M, Narkwa PW. Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naïve individuals in Kumasi, Ghana. PLoS One 2019;14:e0215377. [PMID: 31002687 DOI: 10.1371/journal.pone.0215377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
17 Saing CH, Prem K, Uk P, Chhoun P, Chann N, Tuot S, Mun P, Yi S. Risk factors associated with HIV and hepatitis C virus co-infection among people who inject drugs in Cambodia. Int J Drug Policy 2020;86:102974. [PMID: 33068831 DOI: 10.1016/j.drugpo.2020.102974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 De Weggheleire A, An S, De Baetselier I, Soeung P, Keath H, So V, Ros S, Teav S, Smekens B, Buyze J, Florence E, van Griensven J, Thai S, Francque S, Lynen L. A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening. PLoS One 2017;12:e0183530. [PMID: 28832660 DOI: 10.1371/journal.pone.0183530] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
19 Ananworanich J, Avihingsanon A. HIV and noncommunicable diseases: the Asian perspective. J Acquir Immune Defic Syndr 2014;67 Suppl 1:S99-103. [PMID: 25117967 DOI: 10.1097/QAI.0000000000000262] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Maponga TG, McNaughton AL, van Schalkwyk M, Hugo S, Nwankwo C, Taljaard J, Mokaya J, Smith DA, van Vuuren C, Goedhals D, Gabriel S, Andersson MI, Preiser W, van Rensburg C, Matthews PC. Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. J Infect 2020;81:121-30. [PMID: 32360882 DOI: 10.1016/j.jinf.2020.04.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Walsh N, Durier N, Khwairakpam G, Sohn AH, Lo Y. The hepatitis C treatment revolution: how to avoid Asia missing out. Journal of Virus Eradication 2015;1:272-5. [DOI: 10.1016/s2055-6640(20)30924-9] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
22 Yi S, Mun P, Chhoun P, Chann N, Tuot S, Mburu G. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey. Harm Reduct J 2019;16:29. [PMID: 31036011 DOI: 10.1186/s12954-019-0299-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
23 Anderson M, Gaseitsiwe S, Moyo S, Thami KP, Mohammed T, Setlhare D, Sebunya TK, Powell EA, Makhema J, Blackard JT, Marlink R, Essex M, Musonda RM. Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana. Open Forum Infect Dis 2016;3:ofw140. [PMID: 27800524 DOI: 10.1093/ofid/ofw140] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
24 Lynch E, Falq G, Sun C, Bunchhoeung PDT, Huerga H, Loarec A, Dousset JP, Marquardt T, Paih ML, Maman D. Hepatitis C viraemic and seroprevalence and risk factors for positivity in Northwest Cambodia: a household cross-sectional serosurvey. BMC Infect Dis 2021;21:223. [PMID: 33637051 DOI: 10.1186/s12879-021-05826-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Gupta S, Malhotra B, Tiwari JK, Khandelwal PD, Maheshwari RK. Cluster of differentiation 4+ T-cell counts and human immunodeficiency virus-1 viral load in patients coinfected with hepatitis B virus and hepatitis C virus. J Lab Physicians 2018;10:162-7. [PMID: 29692581 DOI: 10.4103/JLP.JLP_37_17] [Reference Citation Analysis]
26 Phinius BB, Anderson M, Bhebhe L, Baruti K, Manowe G, Choga WT, Mupfumi L, Mbangiwa T, Mudanga M, Moyo S, Marlink R, Blackard JT, Gaseitsiwe S. Increased Prevalence of Liver Fibrosis and HIV Viremia among Patients with HIV, HBV, and Tuberculosis in Botswana. Pathogens 2020;9:E950. [PMID: 33202597 DOI: 10.3390/pathogens9110950] [Reference Citation Analysis]
27 Su S, Fairley CK, Sasadeusz J, He J, Wei X, Zeng H, Jing J, Mao L, Chen X, Zhang L. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome. J Med Virol 2018;90:518-25. [PMID: 29091279 DOI: 10.1002/jmv.24988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Boettiger DC, Kerr S, Ditangco R, Chaiwarith R, Li PC, Merati TP, Pham TT, Kiertiburanakul S, Kumarasamy N, Vonthanak S, Lee CK, Van Kinh N, Pujari S, Wong WW, Kamarulzaman A, Zhang F, Yunihastuti E, Choi JY, Oka S, Ng OT, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Law M; TREAT Asia HIV Observational Database. Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database. Antivir Ther 2016;21:27-35. [PMID: 26069150 DOI: 10.3851/IMP2972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
29 Mburu G, Chhoun P, Chann N, Tuot S, Mun P, Yi S. Prevalence and risk factors of HIV infection among people who inject drugs in Cambodia: findings from a national survey. Subst Abuse Treat Prev Policy 2019;14:42. [PMID: 31623645 DOI: 10.1186/s13011-019-0232-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
30 De Clercq E. Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace: Treatment of hepatitis C accelerating. Rev Med Virol 2015;25:254-67. [DOI: 10.1002/rmv.1842] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
31 Lay P, An S, Soeung S, Srey PS, Thai S, Lynen L, Griensven JV. Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes. PLoS One 2017;12:e0185348. [PMID: 29136011 DOI: 10.1371/journal.pone.0185348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]